Laboratory Developed Tests (LDTs) Regulatory Guide: The 2024 Rule, Court Vacatur, and What Comes Next
Complete guide to laboratory developed test regulation in 2026 — FDA's vacated 2024 final rule, the ACLA court decision, current CLIA oversight, enforcement discretion status, and what laboratories must do now.
The LDT Regulatory Landscape Has Changed — Again
Laboratory developed tests sit at the intersection of clinical diagnostics, regulatory policy, and federal court jurisdiction. In the span of twelve months, the FDA attempted to bring LDTs under medical device oversight through a sweeping final rule, a federal court struck that rule down, and the FDA formally vacated it. As of April 2026, the regulatory status quo has been restored — but the underlying policy questions remain unresolved.
This guide traces the full arc of LDT regulation: what the 2024 final rule proposed, why the court rejected it, what the current enforcement framework looks like, and what laboratories should expect next.
What Are Laboratory Developed Tests (LDTs)?
A laboratory developed test is an in vitro diagnostic (IVD) test that is designed, manufactured, and used within a single clinical laboratory. Unlike commercially distributed test kits, LDTs are not sold to other laboratories or directly to consumers. Instead, healthcare providers send specimens to the laboratory that developed the test, where laboratory personnel perform the analysis and return results.
LDTs serve critical roles in areas where commercial tests are unavailable or insufficient:
- Rare disease diagnostics where no FDA-cleared alternative exists
- Oncology companion diagnostics that guide personalized treatment
- Infectious disease detection including emerging pathogens
- Genetic and genomic testing for inherited conditions
- Pharmacogenomics for drug metabolism profiling
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) estimates that nearly 80,000 LDTs are offered by approximately 1,200 laboratories across the United States.
How LDTs Differ from Commercial IVDs
| Dimension | Laboratory Developed Test | Commercial IVD |
|---|---|---|
| Manufacturing | Designed and produced in a single lab | Mass-produced and distributed |
| Distribution | Used only within the developing laboratory | Sold to multiple laboratories |
| Regulatory oversight | CLIA (CMS), with FDA enforcement discretion | FDA premarket review required |
| Premarket review | Not required under current policy | 510(k), De Novo, or PMA required |
| Quality system | CLIA quality requirements | 21 CFR Part 820 / QMSR |
| Registration | CLIA certificate | FDA establishment registration |
| Labeling | Laboratory-specific protocols | FDA-compliant labeling (21 CFR 809) |
The Regulatory History of LDTs
1976–2024: Enforcement Discretion
When Congress passed the Medical Device Amendments of 1976, FDA gained authority to regulate devices, including IVDs. However, FDA consistently exercised enforcement discretion over LDTs, meaning it chose not to enforce most device requirements against laboratories that developed and used tests in-house.
This policy reflected the 1970s reality: LDTs were relatively simple, manually performed tests used by pathologists in small volumes for individual patients. FDA recognized that CLIA — administered by the Centers for Medicare & Medicaid Services (CMS) — provided oversight of laboratory quality, personnel qualifications, and test validation.
Over the decades, LDTs evolved dramatically. Modern LDTs include complex genomic sequencing panels, next-generation sequencing (NGS) assays, and AI-powered diagnostic algorithms. These tests can reach millions of patients, raising questions about whether CLIA oversight alone is sufficient to assure safety and effectiveness.
Key Regulatory Milestones
| Year | Event |
|---|---|
| 1967 | Clinical Laboratory Improvement Act (CLIA '67) establishes lab standards |
| 1976 | Medical Device Amendments — FDA gains device authority but exercises discretion for LDTs |
| 1988 | CLIA '88 strengthens laboratory quality requirements |
| 2010 | FDA begins holding public meetings on LDT oversight |
| 2014 | FDA releases draft guidance proposing a risk-based LDT framework |
| 2017 | FDA announces it will pursue a new approach through notice-and-comment rulemaking |
| 2023 | VALID Act reintroduced in Congress but does not advance |
| 2024 | FDA issues final rule on LDT regulation (May 6) |
| 2025 | Federal court vacates the rule (March 31); FDA formally rescinds it (September 19) |
| 2026 | Enforcement discretion continues; legislative solutions debated |
The 2024 FDA Final Rule: What It Proposed
On May 6, 2024, FDA published a final rule amending the definition of "in vitro diagnostic products" in 21 CFR 809.3(a) to explicitly include "when the manufacturer of these products is a laboratory." This single definitional change was intended to bring all LDTs within FDA's medical device regulatory framework.
The Five-Stage Phaseout Plan
The rule included a four-year, five-stage transition to phase out enforcement discretion:
| Stage | Effective Date | Requirements |
|---|---|---|
| Stage 1 | May 6, 2025 | Medical Device Reporting (MDR); Correction and Removal Reporting; Quality System requirements for complaint files |
| Stage 2 | May 6, 2026 | Registration and Listing; Labeling requirements; Investigational requirements (IDE/IRB) |
| Stage 3 | May 6, 2027 | Full Quality System requirements (including design controls, CAPA, purchasing controls, acceptance activities) |
| Stage 4 | November 6, 2027 | Premarket review for high-risk IVDs offered as LDTs (Class III / PMA) |
| Stage 5 | May 6, 2028 | Premarket review for moderate and low-risk IVDs requiring premarket submission |
Targeted Enforcement Discretion Policies
The rule included exceptions where FDA would continue exercising enforcement discretion for specific LDT categories:
- LDTs for rare diseases affecting fewer than 4,000 individuals in the US per year
- LDTs with no available commercial alternative for an unmet need
- LDTs performed within the US military or Department of Veterans Affairs health systems
- LDTs for forensic or law enforcement purposes
- LDTs approved by the New York State Clinical Laboratory Evaluation Program (NYS CLEP)
The Cost of the Vacated Rule
FDA estimated that full implementation of the LDT final rule would have cost the laboratory industry between $1.29 billion and $1.37 billion annually. The compliance burden would have fallen disproportionately on smaller laboratories and hospital-based testing programs that lacked the infrastructure for FDA premarket submissions, quality systems under 21 CFR Part 820, and establishment registration. FDA also acknowledged that the rule could disincentivize commercial IVD manufacturers from developing tests that compete with existing LDTs, potentially reducing innovation in both sectors.
American Clinical Laboratory Association v. FDA
The Challenge
The American Clinical Laboratory Association (ACLA), joined by HealthTrackRx and the Association for Molecular Pathology (AMP), filed suit in the US District Court for the Eastern District of Texas, arguing that FDA exceeded its statutory authority under the Federal Food, Drug, and Cosmetic Act (FDCA). The core arguments were:
FDA lacked statutory authority: Congress did not grant FDA explicit authority to regulate LDTs as devices. The FDCA defines devices as articles "intended for use in the diagnosis of disease," but the plaintiffs argued this was never meant to encompass laboratory-developed testing services.
The rule was contrary to law: By amending the regulatory definition rather than obtaining new legislation, FDA effectively created new regulatory obligations without congressional authorization.
The rule was arbitrary and capricious: Under the Administrative Procedure Act (APA), the rule was not supported by the factual record and failed to adequately consider alternatives.
The Court's Decision
On March 31, 2025, the court ruled in favor of the plaintiffs, finding that "FDA's final rule exceeds its authority and is unlawful." The court vacated the rule and remanded to the agency. Key holdings included:
- FDA could not use a definitional amendment to expand its jurisdiction to LDTs
- The historical record showed Congress understood LDTs to be distinct from commercial medical devices
- The ruling invoked the Supreme Court's Loper Bright Enterprises v. Raimondo decision (2024), which overturned Chevron deference and limited agency interpretations of ambiguous statutes
FDA's Response
FDA declined to appeal the ruling. Its notice of appeal deadline was May 30, 2025, but the agency chose not to file. On September 19, 2025, FDA issued a new final rule formally rescinding the 2024 regulation, reverting 21 CFR 809.3(a) to its pre-2024 language and removing the phrase "including when the manufacturer of these products is a laboratory."
Additionally, the House Appropriations Committee included report language in its fiscal year 2026 funding bill directing FDA to suspend enforcement of the vacated rule.
Current Regulatory Framework (April 2026)
FDA Enforcement Discretion Restored
With the rule vacated, FDA has returned to its long-standing policy of enforcement discretion for LDTs that meet the traditional definition:
- Designed, manufactured, and used within a single laboratory
- Intended for clinical use (not distributed commercially)
- The laboratory holds a valid CLIA certificate
Under this framework:
- LDTs do not require FDA premarket review (510(k), De Novo, or PMA)
- LDTs do not require FDA establishment registration or device listing
- FDA does not enforce Quality System (QMSR) requirements against LDT laboratories
- LDTs are not subject to FDA labeling requirements under 21 CFR Part 809
However, enforcement discretion does not extend to IVDs that do not meet the narrow LDT definition. Commercially distributed test kits, direct-to-consumer tests, and tests marketed across multiple laboratories must still comply with all applicable FDA requirements.
CLIA Oversight Remains in Effect
Regardless of FDA's enforcement discretion, all clinical laboratories performing LDTs must comply with CLIA, administered by CMS. CLIA requires:
- CLIA certificate appropriate to test complexity (Certificate of Compliance, Certificate of Accreditation, or Certificate of Registration)
- Personnel qualifications including board-certified laboratory directors, technical supervisors, and testing personnel
- Proficiency testing to demonstrate ongoing analytical accuracy
- Quality control and quality assurance programs
- Analytical validation of each LDT before clinical use (accuracy, precision, reportable range, reference intervals, analytical sensitivity, and analytical specificity)
- Procedure manuals documenting test methodology, specimen requirements, and result interpretation
State-Level Requirements
Some states impose additional requirements beyond CLIA:
| State | Requirement |
|---|---|
| New York | NYS CLEP approval required for all LDTs offered to NY patients; includes clinical validation review |
| Pennsylvania | Laboratory licensure requirements |
| California | Clinical laboratory licensing under CDPH |
| Florida | Agency for Health Care Administration laboratory licensure |
The New York State CLEP program is particularly significant because it performs independent clinical and analytical validation reviews of LDTs, providing a level of oversight that some consider equivalent to FDA premarket review.
What This Means for Laboratories
What Has Not Changed
For the approximately 1,200 laboratories offering LDTs, the immediate practical impact of the court decision and FDA's vacatur is minimal:
- No new FDA registration or listing obligations
- No premarket submissions required
- No QMSR compliance requirements for the LDT itself
- CLIA compliance remains the primary regulatory obligation
What Has Changed: Risk Awareness
Despite the restoration of enforcement discretion, several factors should shape laboratory strategy:
Documentation standards are rising: Even without FDA oversight, payers, health systems, and accreditation bodies increasingly expect robust analytical and clinical validation documentation.
Reimbursement scrutiny: CMS and private payers are tightening coverage requirements for LDTs, particularly those competing with FDA-cleared alternatives. Laboratories should maintain clinical utility evidence.
Liability exposure: Without FDA review, laboratories bear sole responsibility for LDT safety and effectiveness. Robust validation, quality management, and adverse event monitoring are essential risk mitigation strategies.
Competitive landscape: Laboratories that invest in voluntary FDA clearance for their highest-volume LDTs may gain competitive advantages through payer coverage and provider trust.
Strategic Recommendations
| Scenario | Recommendation |
|---|---|
| Rare disease LDT with no commercial alternative | Continue under CLIA; document clinical utility for payers |
| High-volume LDT competing with FDA-cleared tests | Consider voluntary 510(k) submission for competitive positioning |
| Genomic panel (NGS-based) | Maintain robust validation; explore voluntary FDA authorization if seeking broader coverage |
| LDT used in clinical trials | Ensure IDE/IRB compliance per clinical trial requirements |
| Direct-to-consumer test | This does not qualify as an LDT — FDA regulation applies |
Legislative Outlook: The VALID Act and Beyond
The court's decision leaves a regulatory gap that many stakeholders believe Congress should fill. The Verifying Accurate, Leading-edge IVCT Diagnostics (VALID) Act, most recently reintroduced as H.R.2369 in the 118th Congress (2023) by Representatives Larry Bucshon (R-IN) and Diana DeGette (D-CO), proposed a framework for FDA oversight of in vitro clinical tests (IVCTs), including LDTs.
Key provisions of legislative proposals have included:
- A risk-based tiering system for test oversight
- Grandfathering provisions for existing LDTs
- Recognition of CLIA as the baseline oversight framework
- A new category of "in vitro clinical tests" distinct from devices
- Explicit congressional authorization for FDA review of high-risk tests
As of April 2026, no legislation has been enacted. The path forward depends on congressional priorities, stakeholder negotiations, and the political dynamics of healthcare regulation.
Comparison: Current LDT Oversight vs. FDA-Regulated IVDs
| Requirement | LDT (Current) | FDA-Regulated IVD |
|---|---|---|
| Premarket review | Not required | 510(k), De Novo, or PMA |
| Quality system | CLIA quality requirements | QMSR (21 CFR 820) / ISO 13485 |
| Registration & listing | CLIA certificate | FDA establishment registration |
| Labeling | Laboratory protocol | 21 CFR 809 compliant labeling |
| MDR reporting | Not required under FDA | Required under 21 CFR 803 |
| Design controls | Not required under FDA | Required under QMSR |
| Correction & removal reporting | Not required under FDA | Required under 21 CFR 806 |
| Proficiency testing | Required under CLIA | May be required under CLIA |
| Analytical validation | Required under CLIA | Required (510(k) data) |
| Clinical validation | Recommended; required by NY CLEP | Required for PMA/De Novo; varies for 510(k) |
| Advertising/promotion | FTC general oversight | FDA/FTC oversight |
FAQ
Are LDTs completely unregulated?
No. LDTs are regulated under CLIA, which requires analytical validation, proficiency testing, quality control, and personnel qualifications. Some states (notably New York) impose additional clinical validation requirements. The FDA's enforcement discretion means it does not apply device-specific regulations, not that LDTs operate without oversight.
Can FDA still regulate any LDTs?
Yes. FDA has historically exercised enforcement discretion selectively. It may still regulate LDTs that do not meet the traditional definition (e.g., direct-to-consumer tests, tests distributed across multiple laboratories, or tests for high-risk uses during public health emergencies).
What happened to the LDTs that already obtained FDA clearance or approval?
Tests that voluntarily went through FDA review maintain their clearance or approval. However, the court ruling means FDA cannot require other LDTs to follow the same path. Laboratories with voluntarily cleared LDTs may have competitive advantages in reimbursement and market positioning.
Does the QMSR (effective February 2, 2026) apply to LDTs?
No. The QMSR (Quality Management System Regulation) applies to medical device manufacturers subject to FDA jurisdiction. Under the restored enforcement discretion policy, FDA does not enforce QMSR requirements against laboratories developing LDTs. Laboratories must still comply with CLIA quality requirements.
Should my laboratory pursue voluntary FDA clearance for an LDT?
This is a business decision that depends on your test's market position, reimbursement strategy, and competitive landscape. Voluntary clearance can provide payer coverage advantages and competitive differentiation but involves significant cost and time. Consider FDA clearance for high-volume tests competing against commercially available alternatives.
What is the NYS CLEP and how does it affect LDT oversight?
The New York State Clinical Laboratory Evaluation Program (CLEP) requires approval for all laboratory tests offered to New York patients, including LDTs. CLEP performs independent analytical and clinical validation reviews. Some stakeholders have argued that NYS CLEP provides a model for LDT oversight, and the vacated FDA rule had proposed continued enforcement discretion for CLEP-approved LDTs.
Could Congress pass a new law giving FDA authority over LDTs?
Yes. The court's decision was based on FDA exceeding its current statutory authority. Congress could grant FDA explicit authority through new legislation. The VALID Act represented one such attempt, though it has not advanced to enactment. Any future legislation would need to balance patient safety, innovation, laboratory access, and regulatory burden.
What should laboratories do now to prepare for potential future regulation?
- Maintain comprehensive analytical and clinical validation documentation
- Establish quality management practices aligned with ISO 15189 or CLIA requirements
- Monitor legislative developments and participate in industry advocacy
- Build relationships with regulatory consultants who understand both CLIA and FDA frameworks
- Track payer coverage policies that may require evidence beyond CLIA compliance
- Document adverse events and complaints through internal quality systems even without FDA MDR obligations
Key Takeaways
The FDA's 2024 attempt to regulate LDTs as medical devices was struck down by the federal court in March 2025 and formally vacated in September 2025. As of April 2026, enforcement discretion has been restored. LDTs remain primarily regulated under CLIA, with FDA oversight limited to tests that fall outside the traditional LDT definition. The long-term regulatory path for LDTs will likely depend on congressional action rather than agency rulemaking.